Core Viewpoint - Huahai Pharmaceutical's subsidiary Shanghai Huao Tai Biopharmaceutical Co., Ltd. and Huabo Biopharmaceutical Technology (Shanghai) Co., Ltd. have received approval from the National Medical Products Administration for a new indication for the HB0056 injection project, specifically for atopic dermatitis [1] Group 1 - The HB0056 injection is intended for the treatment of atopic dermatitis and is in the form of an injection [1] - The clinical trial application for the new indication has been accepted and approved by the National Medical Products Administration [1] - The company has invested approximately RMB 91.69 million in the HB0056 project to date [1]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The commercialization of ADC (Antibody-Drug Conjugates) is accelerating, with 20 ADC drugs approved globally, and 6 of them have been in the "billion-dollar club" for two consecutive years [30][31] - The report highlights the increasing competition in the ADC sector, with approximately 60 ADC drugs currently in clinical phase 3 and application stages [30] - Domestic innovative pharmaceutical companies are adopting various strategies for ADC capacity layout, with companies like Rongchang Biopharma transitioning from outsourcing to in-house production, while others like Kelong Biotechnology are building their own production bases [31][32] Summary by Sections Market Review - The pharmaceutical index rose by 0.14% this week, outperforming the CSI 300 index by 1.47 percentage points, ranking 15th in industry performance [10] - Year-to-date, the pharmaceutical index has increased by 3.28%, also outperforming the CSI 300 index by 2.99 percentage points, ranking 23rd [10] Individual Stock Performance - In the A-share market, 255 out of 479 pharmaceutical stocks rose, with the top five performers being Guangshengtang (+29.83%), Haixiang Pharmaceutical (+18.64%), and Meidixi (+18.04%) [20] - In the Hong Kong market, 38 out of 116 pharmaceutical stocks rose, with the top performers including Yiteng Jiahe (+14%) and Kedi-B (+9.96%) [24] Industry News and Policies - The newly revised "Regulations on the Implementation of the Drug Administration Law" supports segmented contract manufacturing and commercial-scale drug sales, providing a foundation for ADC commercialization cooperation [32] - Notable industry developments include Novartis's application for Ianalumab in China and Johnson & Johnson's approval of Daratumumab injection for multiple myeloma treatment [27][28] Weekly Insights - The ADC commercialization battle has begun, with a significant increase in demand for ADC production capacity, leading to a supply-demand imbalance [30] - Major CXO companies are expanding ADC production capacity, with companies like WuXi AppTec acquiring East Yao Pharmaceutical to meet rising orders [31]

前沿生物（688221.SH）2月9日在投资者互动平台表示，FB7012为拟治疗高尿酸血症与痛风的小核酸药 物，截至目前尚处于临床前研究。公司将按照信息披露规则对在研项目的进展情况履行信息披露义务， 请持续关注公司公告。药品开发具有一定的不确定性，请您注意投资风险。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：FB7012是否进入I期临床试验？试验结果如何？ ...

礼来(LLY.N)盘前上涨2.2%，此前Hims & Hers撤回了减肥药的上市计划。 本文源自：金融界AI电报 ...

每经AI快讯，2月9日，礼来公司（Eli Lilly）盘前股价上涨2.2%。 ...

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) reported a total operating revenue of 3.635 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 0.13%, while the net profit attributable to shareholders increased by 24.74% to 288 million yuan [1] Group 1: Financial Performance - The total operating revenue for 2025 was 3.635 billion yuan, showing a slight increase of 0.13% compared to the previous year [1] - The net profit attributable to shareholders reached 288 million yuan, marking a significant year-on-year growth of 24.74% [1] Group 2: Growth Drivers - The primary reasons for the performance growth include stable revenue growth from core industrial enterprises and improved profitability [1] - The acquisition of stakes in two subsidiaries, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (28.92% stake) and Hunan Qianjin Xieli Pharmaceutical Co., Ltd. (68% stake), contributed to the financial results, with these stakes being consolidated under the new ownership structure starting in October and November 2025, respectively [1]

Group 1 - Company announced an exclusive commercialization agreement with Maikouote for the new drug MT1013, aimed at treating secondary hyperparathyroidism (SHPT), with a transaction value of up to 1.24 billion RMB (179 million USD) [2] - The agreement includes an upfront payment of 200 million RMB and potential milestone payments of up to 1.04 billion RMB, with ongoing Phase III clinical trials funded by Maikouote [2] - The company also received approval from the National Medical Products Administration of China for its drug Velsipity, which treats moderate to severe active ulcerative colitis (UC) in adults who do not respond adequately to traditional treatments [2][3] Group 2 - Velsipity is a new generation high-selectivity S1P receptor modulator, approved based on two Phase III studies demonstrating statistical significance and clinical relevance across all primary and secondary efficacy endpoints [3] - Following these announcements, the company's stock price increased by 5.5% over two trading days, with a year-to-date increase of 7.2% [4]

Core Viewpoint - North China Pharmaceutical (600812.SH) announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., has received the drug registration certificate for Cefprozil tablets (0.25g) from the National Medical Products Administration, marking a significant development in its antibiotic portfolio [1] Group 1: Product Approval - The drug Cefprozil is classified as a second-generation cephalosporin antibiotic [1] - The approved indications for Cefprozil in China include treatment for mild to moderate infections caused by sensitive bacteria, such as upper respiratory infections, lower respiratory infections, and skin and soft tissue infections [1] Group 2: Indications - Specific approved indications include: 1. Upper respiratory infections: Streptococcal pharyngitis/tonsillitis, otitis media, and acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [1] 2. Lower respiratory infections: Acute bronchitis and exacerbations of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [1] 3. Skin and soft tissue infections: Non-complicated infections caused by Staphylococcus aureus and Streptococcus pyogenes, with the note that abscesses may require surgical drainage [1]

Group 1 - Core viewpoint: Goldman Sachs has reiterated a "Buy" rating for Eli Lilly (LLY.US) and raised the target price from $114.5 billion to $126 billion, indicating strong confidence in the company's growth prospects despite increasing pricing pressures in the obesity drug market [1] - Eli Lilly's 2026 earnings guidance suggests approximately 25% year-over-year revenue growth, reflecting sustained market confidence in the obesity drug sector [1] - The company plans to launch orforglipron in the U.S. in the second quarter, with most international markets expected to follow in 2027, according to Ken Custer, head of cardiovascular metabolic health at Eli Lilly [1] Group 2 - Eli Lilly's stock price closed at $1058.18, up 3.66%, with a pre-market price of $1082.32, reflecting a 2.28% increase [2] - The stock's trading volume was 4.8871 million, with a market capitalization of $1 trillion [2] - The price-to-earnings ratio is 46.11, and the stock has a 52-week high of $1133.95, which is 31.03% lower than the current price [2]

消息面上，远程医疗企业Hims & Hers Health宣布下架售价49美元的仿制减肥药。Hims & Hers于上周四 宣布推出该仿制减肥药，其售价较诺和诺德的Wegovy便宜约100美元。随后，诺和诺德发声明称，非法 Wegovy复方制剂风险巨大，将对Hims&Hers采取法律行动；美国食品药品监督管理局亦对其发出警 告。Hims & Hers表示，自从在平台上推出仿制减肥药司美格鲁肽药丸以来，公司已与整个行业的利益 持份者进行建设性的对话，目前已决定停止提供相关的治疗。(格隆汇) 诺和诺德(NVO.US)盘前涨6.6%，报50.79美元。Hims & Hers Health(HIMS.US)盘前跌近14%，报19.81美 元。 ...